NeOnc Technologies released updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent Grade III/IV IDH1-Mutant Astrocytoma.
Expanded clinical experience shows additional long-term survival and radiographic remission.
Treatment with intranasal NEO100 resulted in significant radiographic remission in 24% of patients.
Radiographic Response
24% of patients achieved significant radiographic remission, exceeding response rates of salvage therapies.
Progression-Free Survival (PFS-6)
44% of patients achieved 6-month progression-free survival, surpassing historical benchmarks for IDH1-mutant gliomas.
Long-Term Survival
36% of patients demonstrated durable survival ≥18 months post-initiation of NEO100.
Tolerability
No significant toxicity observed with prolonged intranasal administration of NEO100.
- The updated data reinforce NEO100 as a potential game-changer for patients with recurrent IDH1-mutant high-grade gliomas.
- The outcomes suggest a shift towards durable disease control in neuro-oncology.
- Experts view NEO100 as a first-in-class therapy capable of inducing sustained radiographic remission and long-term survival in recurrent gliomas.
The expanding dataset signifies a critical value-inflection point for NeOnc, offering a potential shift towards durable disease control in the neuro-oncology field.